72194-57-1
Chemical Structure
Pyr-Pro-Arg-pNA
Synonym(s): S-2366
- CAS No.: 72194-57-1
- Formula:C22H30N8O6
- Molecular Weight:502.52
IUPAC Name: (S)-N-((S)-5-guanidino-1-((4-nitrophenyl)amino)-1-oxopentan-2-yl)-1-((S)-5-oxopyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide
InChIKey: WPVINHLVHHPBMK-ULQDDVLXSA-N
SMILES: O=C([C@@H]1CCC(N1)=O)N2[C@@H](CCC2)C(N[C@@H](CCCNC(N)=N)C(NC3=CC=C(C=C3)[N+]([O-])=O)=O)=O
Biological Activity: Pyr-Pro-Arg-pNA (S-2366) is a chromogenic peptidyl substrate, and a noncompetitive inhibitor that occupies the active sites of FXIa and FXIa-LC to block factor IX activation. Pyr-Pro-Arg-pNA functions as a hydrolyzable substrate for FXIa’s catalytic domain, human APC, murine APC, and purified plasma kallikrein[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pyr-Pro-Arg-pNA | Pyr-Pro-Arg-pNA (S-2366) is a chromogenic peptidyl substrate, and a noncompetitive inhibitor that occupies the active sites of FXIa and FXIa-LC to block factor IX activation. Pyr-Pro-Arg-pNA functions as a hydrolyzable substrate for FXIa’s catalytic domain, human APC, murine APC, and purified plasma kallikrein. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sinha D, et al. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation. Biochemistry. 2007;46(34):9830-9839. [Content Brief]
- [2]. Miller T N. The molecular interactions of the catalytic domain of factor XIa (FXIa): Catalysis of substrates IX and S-2366, inhibition by the Kunitz protease inhibitory domain (KPI) of Protease Nexin 2 (PN2), and binding to the surface of activated platelets[M]. Temple University, 2007.
- [3]. Fernández JA, et al. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis. 2003 May-Jun;30(3):271-6. [Content Brief]
- [4]. Briseid K, et al. Part of purified human plasma kallikrein removed together with a remaining IgG fraction--immunoblot experiments and functional tests. Scand J Clin Lab Invest. 2002;62(1):21-24. [Content Brief]
